Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study

European Journal of Contraception and Reproductive Health Care

Volumn 17, Issue 1, 2012, Pages 79-88

  Short, Mary ^a   Dallay, Dominique ^b   Omokanye, Salmon ^c   Hanisch, Jens Ulrich ^d   Inki, Pirjo ^d  

^a Rock Court Medical Centre ^*  (Ireland)

^b HÔPITAL PELLEGRIN   (France)

^c Central Health Clinic   (United Kingdom)

^d BAYER PHARMA AG   (Germany)

Author keywords

Bleeding pattern; Continuation rate; Contraception; Discontinuation; Etonogestrel releasing subdermal implant; Levonorgestrel releasing intrauterine system; Life table; Satisfaction

Indexed keywords

ETONOGESTREL; LEVONORGESTREL;

ACNE; ADULT; ARTICLE; BLEEDING; DEPRESSION; DRUG RELEASE; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; HUMAN; IMPLANT; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; METRORRHAGIA; MOOD CHANGE; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; OVARY CYST; PARANOIA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTHESIS FAILURE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DESOGESTREL; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PATIENT ACCEPTANCE OF HEALTH CARE; PROGESTERONE CONGENERS; QUALITATIVE RESEARCH;

EID: 84855858733     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2011.636088     Document Type: Article

References (12)

1. Mansour D, Inki P, Gemzell-Danielsson K. Effi cacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15: 4-16.
2. National Institute for Health and Clinical Excellence. Long-acting reversible contraception. Clinical Guideline 30. London: RCOG Press 2005. Accessed 18 July 2011 from: www.nice.org.uk/CG030.
3. Trussell J, Lalla AM, Doan QV, e t al. Cost-effectiveness of contraceptives in the United States. Contraception 2009;79:5-14.
4. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: Increasing use of long-acting reversible contraception. Hum Reprod Update 2011;17:121-37.
5. ACOG Committee Opinion no 450: Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009;114: 1434-8.
6. Heimovitch S. Profi le of long-acting contraceptive method users in Europe. Eur J Contracept Reprod Health Care 2009;14:187-95.
7. Peipert JF, Zhao Q, Allsworth JE, e t al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105-13.
8. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527-32.
9. Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, e t al. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada, Spain. Contraception 2009;80:457-462.
10. Mansour D, Bahamondes L, Critchley H, e t al. The management of unacceptable bleeding patterns in etonogestrel- releasing contraceptive implant users. Contraception 2011;83:202-10.
11. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nation-wide study of 17,360 users. BJOG 2000;107:335-9. (Pubitemid 30145374)
12. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287-89. (Pubitemid 44373888)